Cantor Fitzgerald’s Ibere Pharmaceuticals IBER Stock Holding History

Cantor Fitzgerald’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-112,050	Closed	-$1.13M	–	819
2022 Q4	$1.13M	Hold	112,050	–	–	0.02%	380
2022 Q3	$1.11M	Hold	112,050	–	–	0.02%	412
2022 Q2	$1.1M	Buy	+112,050	New	+$1.1M	0.02%	446

Cantor Fitzgerald's IBER Position: Q1 2023 in Review

Cantor Fitzgerald sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 112,050 shares — an estimated $1.13M sold.

Cantor Fitzgerald first reported a position in IBER in Q2 2022 and held it in 3 quarters. The position peaked at $1.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Cantor Fitzgerald reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Cantor Fitzgerald sold 112,050 Ibere Pharmaceuticals shares in Q1 2023, an estimated $1.13M.
Cantor Fitzgerald first reported a position in Ibere Pharmaceuticals in Q2 2022 and held it in 3 quarters.
Cantor Fitzgerald's Ibere Pharmaceuticals position peaked at $1.13M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Cantor Fitzgerald's 13F filing for Q1 2023, filed 15 May 2023.